The Wistar Institute

45 articles about The Wistar Institute

• The Wistar Institute and Batavia Biosciences Launch Collaboration to Manufacture and Distribute Wistar’s Rubella Vaccine Globally

  4/29/2020

  The Bill & Melinda Gates Foundation supports international collaboration to expand global access to life-saving vaccines

• 

  Boston Biomedical Launches Cancer Research Alliance with Three Oncology Centers

  12/3/2019

  Boston Biomedical announced it had launched an oncology research alliance with Columbia University, Harvard University and The Wistar Institute.

• Integral Molecular Selected as the First Industry Partner in The Wistar Institute's Biomedical Research Technician Apprenticeship

  9/26/2019

  Integral Molecular, Inc. has been selected by The Wistar Institute, a global leader in cancer, immunology and infectious disease research as the first industry partner for its Biomedical Research Technician Apprenticeship.

• Inovio Receives NIH Funding to Target its dMAb® Technology Against Antimicrobial-Resistant Infection

  9/17/2019

  Inovio Pharmaceuticals, Inc. announced that the company and its collaborator The Wistar Institute have received a $4.6 million National Institutes of Health grant in support of innovative research to tackle antimicrobial resistance employing Inovio's DNA-encoded monoclonal antibodies platform.

• IMV Announces Research Collaboration with The Wistar Institute to Develop New Targeted Immunotherapy Against the Common BRAF Cancer Mutation

  9/4/2019

  IMV Inc. announced a collaboration with The Wistar Institute and Meenhard Herlyn, D.V.M., D.Sc., professor in the Molecular and Cellular Oncogenesis Program and director of Wistar’s Melanoma Research Center.

• Anixa Biosciences Extends Collaborative Research Agreement with The Wistar Institute and Leading Myeloid-derived Suppressor Cell Researcher Dmitry I. Gabrilovich, M.D., Ph.D.

  2/21/2019

  Anixa Biosciences, Inc. announced it has extended its collaboration with The Wistar Institute and Dmitry I. Gabrilovich, M.D., Ph.D. Gabrilovich is a pioneer in the field of myeloid-derived suppressor cell (MDSC) biology and its roles in cancer progression and therapy response.

• Cullinan Oncology to Develop Novel EBNA1 Inhibitor Discovered by The Wistar Institute

  1/30/2019

  First-in-class small molecule targeting EBV-driven cancers to enter Phase 1 in 2019

• Harbour BioMed and The Wistar Institute Join Forces to Advance Novel Antibody Therapies for Cancer and Infectious Diseases

  6/4/2018

  Harbour BioMed and The Wistar Institute announced that they have entered into a multi-year, multifaceted research collaboration to co-discover novel antibodies for the treatment of cancer and infectious diseases.

• Innate Biologics, LLC Enters Into Collaboration Agreement With The Wistar Institute to Develop Anti-Inflammatory Protein Platform

  3/21/2018

  Innate Biologics has entered into a collaborative research agreement with The Wistar Institute, an international leader in biomedical research.

• Inovio and The Wistar Institute Receive More Than $4.6M in R&D Funding to Advance Vaccines Against Tuberculosis & Malaria

  2/12/2018

  The grants were from the Bill & Melinda Gates Foundation and the (NIH.

• Science Center's QED Program Awards $600,000 to Advance the Commercialization of Three University Technologies Awards Given to New Jersey Institute of Technology, Temple University and The Wistar Institute

  1/30/2018

  The awardees were selected from a pool of 54 applicants from 12 academic and research institutions in Pennsylvania, New Jersey and Delaware.

• The Wistar Institute And BioTime Subsidiary OncoCyte Corporation Expand Agreement To Develop Molecular Diagnostic Test For The Detection Of Lung Cancer

  8/18/2015

• BioTime Release: OncoCyte Corporation’s Collaborators At The Wistar Institute Present Positive Clinical Interim Results Of Blood-Based Diagnostic Test For Non-Invasive Detection Of Lung Cancer

  5/19/2015

• Kerafast And The Wistar Institute Announce Collaboration Through The Kerafast Fellows Program

  3/16/2015

• BioTime’s Subsidiary OncoCyte Corporation Announces Completion Of Multi-Site Clinical Study Of Lung Cancer Diagnostic By Collaborators At The Wistar Institute

  10/3/2014

• "Rewired" Mice Show Signs Of Longer Lives With Fewer Illnesses, The Wistar Institute Study

  8/4/2014

• BioTime’s Subsidiary OncoCyte Corporation and The Wistar Institute to Collaboratively Develop Cancer Diagnostics

  10/15/2013

• ReCyte Therapeutics and OncoCyte Corporation Release: BioTime Licenses Technology for Key Regulatory Gene Underlying Cancer and Stem Cell Reprogramming from The Wistar Institute

  1/24/2012

• Melanoma Patients Offered New Hope with Drug Combos, The Wistar Institute Study

  12/17/2010

• One Company, The Wistar Institute, Aims to Re-purpose a Smallpox Vaccine to Battle HIV

  8/24/2010